Summarized by Masters of Longevity from Longevity Technology.
A look at a veterinary biotech story about a company advancing a drug program aimed at extending healthy lifespan in large dogs, and what that regulatory progress might signal for aging research.
Key Takeaways
- The FDA granted Reasonable Expectation of Effectiveness for LOY-003 targeting large and giant-breed dogs.
- This is the company’s third RXE acceptance following programs for large dogs and for senior dogs.
- The company links GH and IGF-1 signaling differences to size and lifespan and targets that pathway for intervention.
